Marc Andre Marcutte
Partner
Get their honest, personalized take on your startup.
Sign in to pitch Marc →At a glance
- Full Name
- Marc-André Marcotte, CFA
- Title
- Partner & Head of Venture Capital
- Firm
- Sectoral Asset Management
- Firm Type
- Healthcare-focused investment advisor / venture capital investor
- Investment Stage
- Series A or first institutional round for Fonds Medtech Ventures; Series B or later for NEMO
- Target Company Profile
- Innovative healthcare companies, especially biotech and medical technology companies with disruptive therapeutic or diagnostic solutions and global potential
- Sector Focus
- Medical technology, biotechnology, clinical-stage healthcare companies, pharmaceuticals, medical devices, diagnostics
- Geographic Focus
- Canada for Fonds Medtech Ventures; North America and Europe for NEMO
- Location
- Montreal, Quebec, Canada
Background
Marc-André Marcotte is Partner & Head of Venture Capital at Sectoral Asset Management, a Montreal-based healthcare investment firm founded in October 2000. Sectoral describes itself as exclusively focused on global healthcare portfolios and manages both public equity and venture capital healthcare strategies. Its offices are in Montreal, Geneva, and Hong Kong.
Marcotte joined Sectoral Asset Management in 2006. Sectoral’s team profile identifies him as a Deal Partner in the firm’s venture capital group, focused on medical technology investments, and as Head of Venture Capital and a member of Sectoral’s Management Committee.
Before Sectoral, Marcotte worked in medical devices. He was Director of Quality at CryoCath Technologies, a company developing products for atrial fibrillation treatment that was later acquired by Medtronic. Earlier, he worked at Arterial Vascular Engineering in Vancouver as an engineer specializing in angioplasty catheters. Sectoral states he has more than eight years of medical-device development experience.
Marcotte graduated from the University of Sherbrooke in 1997 with a Bachelor of Engineering degree, completed an MBA at HEC Montréal in 2003, and obtained the CFA charter in 2010.
Investment Thesis & Focus
- Sectoral’s venture strategy is healthcare-specific: it backs innovative biotech and medtech companies across North America and Europe through the NEMO family of funds and Canadian medtech companies through Fonds Medtech Ventures.
- Sectoral states: “the best investment opportunity should win the day.” The firm looks for high-potential healthcare companies across biotechnology and medical-device innovation.
- For Fonds Medtech Ventures, the strategy is Canadian medtech, Series A or first institutional round, focused on therapeutic or diagnostic solutions with global disruption potential.
- For NEMO, the strategy is North America and Europe, biotechnology and medical technologies, Series B or later, focused on clinical-stage companies with risk-adjusted return potential and patient impact.
- Sectoral says it leads or co-leads most initial NEMO investments and holds a director seat on most NEMO portfolio-company boards.
- Marcotte’s personal focus is medical technology investments, and his current board seats are concentrated in medtech companies including Neuros, Cagent Vascular, Magnolia Medical Technologies, Iantrek, SecondWave Systems, Antegrade Medical, and Leaflet Solutions.
Notable Investments
- Neuros Medical — Cleveland-based neuromodulation company focused on chronic post-amputation pain; Marcotte serves on the board, and Sectoral lists it as a current NEMO IV medical technology portfolio company.
- Cagent Vascular — Pennsylvania-based company developing serration balloon technology for atherosclerotic cardiovascular disease; Marcotte serves on the board, and Sectoral lists it as a current NEMO IV portfolio company.
- Magnolia Medical Technologies — Developer of blood and bodily-fluid collection devices intended to reduce false positives in sepsis testing; Marcotte serves on the board, and Sectoral lists it as a current NEMO V portfolio company.
- Iantrek — Ophthalmic medical-device company developing micro-interventional glaucoma technologies; Marcotte serves on the board, and Sectoral lists it as a current NEMO V portfolio company.
- SecondWave Systems — Clinical-stage company developing a non-invasive wearable therapeutic ultrasound device for inflammatory diseases; Marcotte serves on the board, and Sectoral lists it as a current FMV I portfolio company.
- Antegrade Medical — Medical-device company developing tools for antegrade approaches in complex cardiology interventions; Marcotte serves on the board, and Sectoral lists it as a current FMV I portfolio company.
- Leaflet Solutions — Pre-clinical cardiac-device company developing a catheter for valve leaflet cutting in valve replacement or repair; Marcotte serves on the board, and Sectoral lists it as a current FMV I portfolio company.
- Shockwave Medical — Medtech company developing intravascular lithotripsy technology; Marcotte was previously a director, and Sectoral lists it as an exited NEMO II-III portfolio company via IPO.
- CurvaFix — Medical-device company developing implantable products for fracture repair in curved bones; Marcotte was previously a director, and Sectoral lists it as a current NEMO IV portfolio company.
- Miach Orthopaedics — Sports-medicine company developing BEAR technology for ACL repair; Marcotte was previously a director, and Sectoral lists it as a current NEMO V portfolio company.
- HighLife Medical — Transcatheter mitral valve replacement company; Marcotte was a board observer, and Sectoral lists it as a current NEMO IV medical technology portfolio company.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.